WIRB-Copernicus Group (WCG) announced the agreement with karmadata, a clinical trial database and decision support application company, today.
karmadata uses big data and cloud technologies to standardize and link healthcare data from various open data sources, such as WHO, NIH, and the CDC, in addition to private sources, like private pharmacy and medical claims, among others.
As part of the agreement, WCG will acquire a suite of proprietary applications from karmadata which, according to the company, are designed to facilitate the management of clinical trial data.
Additionally, WCG will receive an exclusive license to use karmadata’s global library of clinical trial investigator and site data.
“Our clients continue to look for ways to accelerate patient access to innovative medicines by increasing the productivity of the drug development process,” said Donald A. Deieso, PhD, chairman and CEO of WCG.
“Through the acquisition of karmadata’s proprietary clinical trials database and big data technologies, we will be able to help them drive an even greater return on investment in the conduct of clinical trials.”
According to WCG, the addition of karmadata’s global investigator data to the company’s existing investigator/site database will help its clients better plan and conduct site feasibility activities.
“At karmadata, it is our mission to use data and technology to transform the healthcare industry,” said Sean Power, founder and CEO of karmadata.
“We are at a tipping point, and WCG is in a unique position to fundamentally change how sponsors, physicians, and patients experience a clinical trial.”